Not medical advice. Talk to your provider before using any peptide.
Full disclaimerPeptide Schedule Research TeamReviewed Apr 20268 Citations
Exenatide was the first FDA-approved GLP-1 receptor agonist for type 2 diabetes. Both Byetta (twice daily) and Bydureon (weekly) were discontinued in October 2024. Complete clinical data, side effect profile, and transition guidance covered here. Generic options may follow.
5mcg · 2x Daily
Summary: Add 0mL BAC water to your 0.25mg vial. Draw to < 0.1 units on a U-100 syringe for a 5mcg dose. This vial will last 0 doses.
View side effects and safety warnings →
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 5mcg | 2x Daily |
| Moderate | 10mcg | 2x Daily |
| Aggressive | 2mg | Weekly |
Both Byetta and Bydureon BCise were permanently discontinued in October 2024. No generic is available in the US. If you still have pens from before the discontinuation, check the expiration date and don't use anything past it. Byetta came as pre-filled pens. No reconstitution needed. The 5 mcg pen delivered 60 doses (one month at twice daily); the 10 mcg pen also delivered 60 doses. No bacteriostatic water, no insulin syringes, no mixing. Refrigerate before first use; after that, room temperature up to 30 degrees C for 30 days. Bydureon required reconstituting a microsphere suspension immediately before injection. It came in single-dose kits. The BCise autoinjector simplified this, but neither can be replicated by a compounding pharmacy. The biggest mistake most beginners made was timing. Inject within 60 minutes before the meal, not after. If you took it after eating, nausea got worse and glucose control suffered. Keep the two daily doses at least 6 hours apart. If you're on oral medications like antibiotics or birth control pills, take those at least one hour before your exenatide injection. The gastric emptying delay will slow their absorption otherwise. For anyone currently searching for exenatide: transition to semaglutide or tirzepatide with prescriber guidance.
Dosing based on Byetta (exenatide) FDA Prescribing Information (2014) — 14 published references.View all sources →
Cross-check your Exenatide (Byetta / Bydureon) reconstitution math with AI
Pricing updated 2026-04-09
Prices are estimates and vary by source, location, and prescription status.Full pricing breakdown →
Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
Exenatide was the first FDA-approved GLP-1 receptor agonist for type 2 diabetes. Both Byetta (twice daily) and Bydureon (weekly) were discontinued in October 2024. Complete clinical data, side effect profile, and transition guidance covered here. Generic options may follow.